• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Agile Therapeutics, Inc.

    Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Announces Delisting from Nasdaq
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Announces Closing of $7.5 Million Public Offering
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Announces 1-For-50 Reverse Stock Split
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
    From Agile Therapeutics, Inc.
    Via GlobeNewswire
    Tickers AGRX
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.